SAS Output

23-FEB-2019 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1312-ALL, CD22+, REL/REF, Inotuzumab+CVP 1 Y 1 CVP + Inotuzumab dose level 1 38 5 0 0 0 0 0 06/13/2014    
        2 CVP + Inotuzumab dose level 2   5 0 0 0 0 0      
        3 CVP + Inotuzumab dose level 3   11 0 0 0 0 0      
        4 CVP + Inotuzumab dose level 4   5 0 0 0 0 0      
        5 CVP + Inotuzumab dose level 5   11 0 0 0 0 0      
        6 CVP + Inotuzumab MTD   12 12 8 4 1 1      
            49 12 8 4 1 1      
 
  S1318-ALL, Age 65+, Ph±, Blinatumomab 1 T 1 Induction: Ph- 44 31 0 0 0 0 0 06/30/2015 132 52
        2 Induction: Ph+/Ph-like   16 0 0 0 0 0      
            47 0 0 0 0 0      
 
    2 Y 3 Post-remission: Ph- 44 20 0 0 0 0 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   12 0 0 0 0 0      
            32 0 0 0 0 0      
 
    3 Y 5 Maintenance: Ph- 44 14 1 0 0 0 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   10 0 0 0 0 0      
            24 1 0 0 0 0      
 
  S1612-AML/MDS, Age 60+, Aza/Novel Therapeutics 1 T 0 FLT3 Testing 1670 113 108 29 0 0 0 02/02/2018 245 90
            113 108 29 0 0 0      
 
    2 T 1 Azacitidine 1670 26 25 7 0 0 0 02/02/2018    
        2 Azacitidine + Nivolumab   26 26 7 0 0 0      
        3 Azacitidine + Midostaurin   26 25 7 0 0 0      
            78 76 21 0 0 0      
 
  S1712-CML, chronic phase, TKI +/- Ruxolitinib 1 Y 1 Single Agent TKI 84 2 2 2 2 1 0 10/24/2018 144 53
        2 TKI + Ruxolitinib   1 1 1 0 0 0      
            3 3 3 2 1 0      
 
Yes E1910-BCR-ABL-neg, B ALL, Blinatumomab 1 E Total Registrations   106 28 13 4 4 0 06/06/2014 1 86
            106 28 13 4 4 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 1 E Total Registrations   75 0 0 0 0 0 08/06/2012   70
            75 0 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   3 3 3 2 0 0 11/09/2018 138 52
            3 3 3 2 0 0      
 
    1 E Total Registrations   2 2 2 1 0 0 11/09/2018    
            2 2 2 1 0 0      
 
    2 E Total Registrations   1 1 1 1 0 0 11/09/2018    
            1 1 1 1 0 0      
 
  E1910-BCR-ABL-neg, B ALL, Blinatumomab 0 E Total Registrations   146 38 17 6 4 0 06/06/2014 1 86
            146 38 17 6 4 0      
 
    2 E Total Registrations   68 22 11 6 2 0 06/06/2014    
            68 22 11 6 2 0      
 
    3 E Total Registrations   55 17 10 5 3 1 06/06/2014    
            55 17 10 5 3 1      
 
    4 E Total Registrations   22 4 1 1 0 0 06/06/2014    
            22 4 1 1 0 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 0 E Total Registrations   19 0 0 0 0 0 08/06/2012   70
            19 0 0 0 0 0      
 
    2 E Total Registrations   21 0 0 0 0 0 08/06/2012    
            21 0 0 0 0 0      
 
    3 E Total Registrations   11 0 0 0 0 0 08/06/2012    
            11 0 0 0 0 0      
 
  NHLBIMDS-LEUK, National MDS Study 1 E Total Registrations   26 19 10 7 2 2 12/22/2016 212 81
            26 19 10 7 2 2